BioSpace News Archive

Aerin Medical Inc. a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced it has recently closed a $60 million equity financing.

Welldoc Granted 31st Patent for First-in-Class Chronic Care Platform.

Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee.

GenomOncology announced that their Precision Oncology Platform now integrates patients’ prior intervention eligibility criteria to further advance their treatment matching algorithm and decision support capabilities.

The U.S. Digital Therapeutics market size was valued at US$ 1.50 billion in 2021 and is expected to hit US$ 11.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 24.10% from 2022 to 2030.

According to Nova one advisor, The U.S. Hydrochloric Acid market size was valued at US$ 560.9 million in 2021 and is expected to hit US$ 810.2 million by 2030, growing at a compound annual growth rate (CAGR) of 6.8% from 2022 to 2030.

The U.S. Healthcare Finance Solutions market size was valued at US$ 46.9 billion in 2021 and is expected to hit US$ 90.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% from 2022 to 2030.

According to Nova one advisor, The U.S. Stethoscope market size was valued at US$ 145.32 million in 2021 and is expected to hit US$ 221.06 million by 2030, growing at a compound annual growth rate (CAGR) of 8.7% from 2022 to 2030.

The global healthcare smart contracts market was surpassed at USD 1.7 billion in 2021 and is expected to hit around USD 7.9 billion by 2030, growing at a CAGR of 18.61 % from 2022 to 2030.

SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented preclinical regenerative medicine data showing that the company’s proprietary Cell Squeeze® technology can effectively generate dopaminergic neurons from human-induced pluripotent stem cells through the single-step delivery of six RNA that encode for specific fate-determining transcription factors.